Medscape March 11, 2021
Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care.
Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequencing method they developed to improve risk stratification of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The method, which is called ChromoSeq, may be expanded for use in other types of cancer, including solid tumors.
In a proof-of-concept study published online March 11 in The New England Journal of Medicine, the researchers used ChromoSeq to genetically profile 263 patients with AML or MDS treated at the university and then compared the results with results from conventional piecemeal genetic testing.
Whole-genome sequencing identified...
Today's Sponsors
Today's Sponsor